Arrowhead Pharmaceuticals, Inc. (ARWR)
Free
No email, no account, no signup.
Pulling latest news for Arrowhead Pharmaceuticals, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
RNAi therapeutics
Market Cap
$10.5B
We're already tracking Arrowhead Pharmaceuticals, Inc. — here are the latest events we've registered
Recent News
- On May 1, 2026, Arrowhead announced that the Australian Therapeutic Goods Administration (TGA) approved REDEMPLO (plozasiran) for the treatment of familial chylomicronemia syndrome (FCS). This follows the drug's previous regulatory approvals in the United States, Canada, and China. The company is also scheduled to present data at several major healthcare conferences throughout May 2026.
Want to know how this news affects Arrowhead Pharmaceuticals, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Arrowhead Pharmaceuticals, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.